SCHEMBL24329687

SCHEMBL24329687

Cc1ccc(-c2csc(NC(=O)c3cc(C)n(C)n3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.58
▸ SMN1; SMN2 Q16637 6/20 0.58
▸ KDM4E B2RXH2 4/20 0.58
▸ NPC1 O15118 4/20 0.58
▸ RAB9A P51151 4/20 0.58
▸ MAPT P10636 6/20 0.57
▸ HTT P42858 1/20 0.57
▸ MEN1 O00255 5/20 0.56
▸ KMT2A Q03164 5/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ POLB P06746 3/20 0.56
▸ ESR1 P03372 1/20 0.56
▸ ESR2 Q92731 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ THRB P10828 1/20 0.55
▸ GSTO1 P78417 1/20 0.55
▸ USP2 O75604 1/20 0.53
▸ MITF O75030 1/20 0.52
▸ NTSR1 P30989 1/20 0.52
▸ CSNK2A2 P19784 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26658235 0.82 LMNA (0.59) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL22728560 0.80 MEN1 (0.62) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL22728481 0.79 LMNA (0.64) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884109 0.79 LMNA (0.58) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL235190 0.79 KDM4E (0.70) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL12248896 0.78 ADORA3 (0.68) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884117 0.78 MAPT (0.63) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884251 0.78 MAPT (0.64) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL22728476 0.77 LMNA (0.65) LMNASMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL26884349 0.77 KMT2A (0.61) LMNASMN1; SMN2KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 LMNA 4496/4885SMN1; SMN2 4696/4885KDM4E 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback